{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:40:26Z","timestamp":1783698026164,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a devastating progressive disease caused by mutations in the iduronate 2-sulfatase (<jats:italic>IDS<\/jats:italic>) gene. IDS is one of the sulfatase enzymes required for lysosomal degradation of glycosaminoglycans. Mutant proteins linked to diseases are often prone to misfolding. These misfolded proteins accumulate in the endoplasmic reticulum (ER) and are degraded by the ubiquitin\u2013proteasome pathway (ER-associated degradation (ERAD)). The decreased enzyme activities of IDS mutants may be due to accelerated degradation by ERAD. However, intracellular dynamics including degradation of IDS mutants is unexplored. In this report, we examined biochemical and biological characteristics of wild-type (WT) IDS and IDS mutants expressed in HeLa cells. IDS was shown to be glycosylated in the ER and Golgi apparatus and proteolytically cleaved to generate the mature forms in the Golgi apparatus. The mature WT IDS was translocated to the lysosome. In contrast, all IDS mutants we examined were found to accumulate in the ER and could not efficiently translocate to the lysosome. Accumulated IDS mutants in the ER were ubiquitinated by ERAD-related ubiquitin E3 ligase HRD1 followed by degradation via ERAD. Suppressed degradation of \u2018attenuated\u2019 mutant A85T IDS (the late-onset form of MPS II) by inhibiting ERAD components improved translocation to the lysosome and its activities. Our novel findings provide alternative targets to current principal therapies for MPS II. These perspectives provide a potenti\tal framework to develop fundamental therapeutic strategies and agents.<\/jats:p>","DOI":"10.1038\/s41419-018-0871-8","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T07:54:03Z","timestamp":1532418843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II"],"prefix":"10.1038","volume":"9","author":[{"given":"Yosuke","family":"Osaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Kanemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-0171","authenticated-orcid":false,"given":"Masayuki","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsuhisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Orii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Fukao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"key":"871_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. Prevalence of lysosomal storage disorders. JAMA 281, 249\u2013254 (1999).","journal-title":"JAMA"},{"key":"871_CR2","first-page":"104","volume":"10","author":"C Hunter","year":"1917","unstructured":"Hunter, C. A rare disease in two brothers. Proc. R. Soc. Med. 10, 104\u2013116 (1917).","journal-title":"Proc. R. Soc. Med."},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","volume":"70","author":"G Bach","year":"1973","unstructured":"Bach, G., Eisenberg, F. Jr, Cantz, M. & Neufeld, E. F. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc. Natl Acad. Sci. USA 70, 2134\u20132138 (1973).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"871_CR4","first-page":"21","volume":"36","author":"P Li","year":"1999","unstructured":"Li, P., Bellows, A. B. & Thompson, J. N. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J. Med. Genet. 36, 21\u201327 (1999).","journal-title":"J. Med. Genet."},{"key":"871_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama, T. et al. Japan elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol. Genet. Metab. 99, 18\u201325 (2010).","journal-title":"Mol. Genet. Metab."},{"key":"871_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","volume":"90","author":"J Muenzer","year":"2007","unstructured":"Muenzer, J., Gucsavas-Calikoglu, M., McCandless, S. E., Schuetz, T. J. & Kimura, A. A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 90, 329\u2013337 (2007).","journal-title":"Mol. Genet. Metab."},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer, J. et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465\u2013473 (2006).","journal-title":"Genet. Med."},{"key":"871_CR8","doi-asserted-by":"crossref","unstructured":"Kubaski, F. et al. Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II. Biol. Bood Marrow Transplant. 23, 1795\u20131803 (2017).","DOI":"10.1016\/j.bbmt.2017.06.020"},{"key":"871_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer, J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol. Genet. Metab. 111, 63\u201372 (2014).","journal-title":"Mol. Genet. Metab."},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00246-013-0653-0","volume":"34","author":"Y Sato","year":"2013","unstructured":"Sato, Y., Fujiwara, M., Kobayashi, H. & Ida, H. Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy. Pediatr. Cardiol. 34, 2077\u20132079 (2013).","journal-title":"Pediatr. Cardiol."},{"key":"871_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1023\/A:1005525931994","volume":"22","author":"A Vellodi","year":"1999","unstructured":"Vellodi, A. et al. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22, 638\u2013648 (1999).","journal-title":"J. Inherit. Metab. Dis."},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1042\/bj2710075","volume":"271","author":"J Bielicki","year":"1990","unstructured":"Bielicki, J., Freeman, C., Clements, P. R. & Hopwood, J. J. Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties. Biochem. J. 271, 75\u201386 (1990).","journal-title":"Biochem. J."},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","volume":"87","author":"PJ Wilson","year":"1990","unstructured":"Wilson, P. J. et al. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc. Natl Acad. Sci. USA 87, 8531\u20138535 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"871_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0092-8674(95)90314-3","volume":"82","author":"B Schmidt","year":"1995","unstructured":"Schmidt, B., Selmer, T., Ingendoh, A. & von Figura, K. A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. Cell 82, 271\u2013278 (1995).","journal-title":"Cell"},{"issue":"Pt 2","key":"871_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/bj3090425","volume":"309","author":"R Froissart","year":"1995","unstructured":"Froissart, R., Millat, G., Mathieu, M., Bozon, D. & Maire, I. Processing of iduronate 2-sulphatase in human fibroblasts. Biochem. J. 309 (Pt 2), 425\u2013430 (1995).","journal-title":"Biochem. J."},{"key":"871_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15786","volume":"8","author":"M Demydchuk","year":"2017","unstructured":"Demydchuk, M. et al. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase. Nat. Commun. 8, 15786 (2017).","journal-title":"Nat. Commun."},{"key":"871_CR17","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1542\/peds.2008-0999","volume":"124","author":"J Muenzer","year":"2009","unstructured":"Muenzer, J. et al. Multidisciplinary management of Hunter syndrome. Pediatrics 124, e1228\u2013e1239 (2009).","journal-title":"Pediatrics"},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1399-0004.1998.tb02746.x","volume":"53","author":"R Froissart","year":"1998","unstructured":"Froissart, R. et al. Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients. Clin. Genet. 53, 362\u2013368 (1998).","journal-title":"Clin. Genet."},{"key":"871_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","volume":"29","author":"K Sukegawa-Hayasaka","year":"2006","unstructured":"Sukegawa-Hayasaka, K. et al. Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J. Inherit. Metab. Dis. 29, 755\u2013761 (2006).","journal-title":"J. Inherit. Metab. Dis."},{"key":"871_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1083\/jcb.132.3.291","volume":"132","author":"AA McCracken","year":"1996","unstructured":"McCracken, A. A. & Brodsky, J. L. Assembly of ER-associated protein degradation in vitro: dependence on cytosol, calnexin, and ATP. J. Cell. Biol. 132, 291\u2013298 (1996).","journal-title":"J. Cell. Biol."},{"key":"871_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/nrm2546","volume":"9","author":"SS Vembar","year":"2008","unstructured":"Vembar, S. S. & Brodsky, J. L. One step at a time: endoplasmic reticulum-associated degradation. Nat. Rev. Mol. Cell Biol. 9, 944\u2013957 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"871_CR22","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/ncb0805-766","volume":"7","author":"B Meusser","year":"2005","unstructured":"Meusser, B., Hirsch, C., Jarosch, E. & Sommer, T. ERAD: the long road to destruction. Nat. Cell Biol. 7, 766\u2013772 (2005).","journal-title":"Nat. Cell Biol."},{"key":"871_CR23","doi-asserted-by":"crossref","unstructured":"Rubenstein, R. C. & Zeitlin, P. L. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell. Physiol. 278, C259\u2013C267 (2000).","DOI":"10.1152\/ajpcell.2000.278.2.C259"},{"key":"871_CR24","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/emboj\/18.6.1492","volume":"18","author":"GC Meacham","year":"1999","unstructured":"Meacham, G. C. et al. The Hdj-2\/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 18, 1492\u20131505 (1999).","journal-title":"EMBO J."},{"key":"871_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","volume":"83","author":"CL Ward","year":"1995","unstructured":"Ward, C. L., Omura, S. & Kopito, R. R. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83, 121\u2013127 (1995).","journal-title":"Cell"},{"key":"871_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/humu.10041","volume":"19","author":"JL Bobadilla","year":"2002","unstructured":"Bobadilla, J. L., Macek, M. Jr, Fine, J. P. & Farrell, P. M. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum. Mutat. 19, 575\u2013606 (2002).","journal-title":"Hum. Mutat."},{"key":"871_CR27","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1097\/01.ASN.0000027355.41663.14","volume":"13","author":"N Marr","year":"2002","unstructured":"Marr, N. et al. Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus. J. Am. Soc. Nephrol. 13, 2267\u20132277 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"871_CR28","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1091\/mbc.e12-08-0631","volume":"23","author":"YC Tsai","year":"2012","unstructured":"Tsai, Y. C. et al. Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system. Mol. Biol. Cell. 23, 4484\u20134494 (2012).","journal-title":"Mol. Biol. Cell."},{"key":"871_CR29","doi-asserted-by":"crossref","unstructured":"Tan, Y. L. et al. ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher\u2019s disease. Chem. Biol. 21, 967\u2013976 (2014).","DOI":"10.1016\/j.chembiol.2014.06.008"},{"key":"871_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/humu.20676","volume":"29","author":"KS Hruska","year":"2008","unstructured":"Hruska, K. S., LaMarca, M. E., Scott, C. R. & Sidransky, E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum. Mutat. 29, 567\u2013583 (2008).","journal-title":"Hum. Mutat."},{"key":"871_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/humu.1380060206","volume":"6","author":"K Sukegawa","year":"1995","unstructured":"Sukegawa, K. et al. Mucopolysaccharidosis type II (Hunter disease): identification and characterization of eight point mutations in the iduronate-2-sulfatase gene in Japanese patients. Hum. Mutat. 6, 136\u2013143 (1995).","journal-title":"Hum. Mutat."},{"key":"871_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1098-1004(1997)10:5<361::AID-HUMU5>3.0.CO;2-I","volume":"10","author":"K Sukegawa","year":"1997","unstructured":"Sukegawa, K. et al. Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Hum. Mutat. 10, 361\u2013367 (1997).","journal-title":"Hum. Mutat."},{"key":"871_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1023\/A:1005363414792","volume":"21","author":"K Isogai","year":"1998","unstructured":"Isogai, K. et al. Mutation analysis in the iduronate-2-sulphatase gene in 43 Japanese patients with mucopolysaccharidosis type II (Hunter disease). J. Inherit. Metab. Dis. 21, 60\u201370 (1998).","journal-title":"J. Inherit. Metab. Dis."},{"key":"871_CR34","doi-asserted-by":"crossref","unstructured":"Froissart, R., Da Silva, I. M. & Maire, I. Mucopolysaccharidosis type II: an update on mutation spectrum. Acta Paediatrica (Oslo, Norway: 1992) 96, 71\u201377 (2007).","DOI":"10.1111\/j.1651-2227.2007.00213.x"},{"key":"871_CR35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1172\/JCI0216886","volume":"110","author":"RJ Kaufman","year":"2002","unstructured":"Kaufman, R. J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 110, 1389\u20131398 (2002).","journal-title":"J. Clin. Invest."},{"key":"871_CR36","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1172\/JCI0216784","volume":"110","author":"D Ron","year":"2002","unstructured":"Ron, D. Translational control in the endoplasmic reticulum stress response. J. Clin. Invest. 110, 1383\u20131388 (2002).","journal-title":"J. Clin. Invest."},{"key":"871_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/16729","volume":"397","author":"HP Harding","year":"1999","unstructured":"Harding, H. P., Zhang, Y. & Ron, D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271\u2013274 (1999).","journal-title":"Nature"},{"key":"871_CR38","doi-asserted-by":"crossref","unstructured":"Yoshida, H. et al. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol. Cell. Biol. 20, 6755\u20136767 (2000).","DOI":"10.1128\/MCB.20.18.6755-6767.2000"},{"key":"871_CR39","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1101\/gad.12.12.1812","volume":"12","author":"W Tirasophon","year":"1998","unstructured":"Tirasophon, W., Welihinda, A. A. & Kaufman, R. J. A stress response pathway from the endoplasmic reticulum to the nucleus requires a novel bifunctional protein kinase\/endoribonuclease (Ire1p) in mammalian cells. Genes & Dev. 12, 1812\u20131824 (1998).","journal-title":"Genes & Dev."},{"key":"871_CR40","doi-asserted-by":"crossref","unstructured":"Bjorkoy, G. et al. p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell. Biol. 171, 603\u2013614 (2005).","DOI":"10.1083\/jcb.200507002"},{"key":"871_CR41","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1242\/jcs.206847","volume":"130","author":"J Schulz","year":"2017","unstructured":"Schulz, J. et al. Conserved cytoplasmic domains promote Hrd1 ubiquitin ligase complex formation for ER-associated degradation (ERAD). J. Cell. Sci. 130, 3322\u20133335 (2017).","journal-title":"J. Cell. Sci."},{"key":"871_CR42","doi-asserted-by":"publisher","first-page":"e0172721","DOI":"10.1371\/journal.pone.0172721","volume":"12","author":"EC Cook","year":"2017","unstructured":"Cook, E. C. et al. Identification of the ER-resident E3 ubiquitin ligase RNF145 as a novel LXR-regulated gene. PLoS. One. 12, e0172721 (2017).","journal-title":"PLoS. One."},{"key":"871_CR43","doi-asserted-by":"publisher","first-page":"e52070","DOI":"10.1371\/journal.pone.0052070","volume":"7","author":"M Wilke","year":"2012","unstructured":"Wilke, M., Bot, A., Jorna, H., Scholte, B. J. & de Jonge, H. R. Rescue of murine F508del CFTR activity in native intestine by low temperature and proteasome inhibitors. PLoS. ONE. 7, e52070 (2012).","journal-title":"PLoS. One."},{"key":"871_CR44","doi-asserted-by":"publisher","first-page":"17369","DOI":"10.1074\/jbc.M600509200","volume":"281","author":"N Vij","year":"2006","unstructured":"Vij, N., Fang, S. & Zeitlin, P. L. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J. Biol. Chem. 281, 17369\u201317378 (2006).","journal-title":"J. Biol. Chem."},{"key":"871_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1091\/mbc.e04-05-0434","volume":"16","author":"Y Shen","year":"2005","unstructured":"Shen, Y. & Hendershot, L. M. ERdj3, a stress-inducible endoplasmic reticulum DnaJ homologue, serves as a cofactor for BiP\u2019s interactions with unfolded substrates. Mol. Biol. Cell. 16, 40\u201350 (2005).","journal-title":"Mol. Biol. Cell."},{"key":"871_CR46","doi-asserted-by":"publisher","unstructured":"Hoshina, H. et al. Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II. Mol. Genet. Metab. https:\/\/doi.org\/10.1016\/j.ymgme.2017.12.428 (2017).","DOI":"10.1016\/j.ymgme.2017.12.428"},{"key":"871_CR47","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.semcdb.2014.12.001","volume":"41","author":"A Tannous","year":"2015","unstructured":"Tannous, A., Pisoni, G. B., Hebert, D. N. & Molinari, M. N-linked sugar-regulated protein folding and quality control in the ER. Semin. Cell. Dev. Biol. 41, 79\u201389 (2015).","journal-title":"Semin. Cell. Dev. Biol."},{"key":"871_CR48","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nature01891","volume":"424","author":"F Chiti","year":"2003","unstructured":"Chiti, F., Stefani, M., Taddei, N., Ramponi, G. & Dobson, C. M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805\u2013808 (2003).","journal-title":"Nature"},{"key":"871_CR49","doi-asserted-by":"crossref","unstructured":"Alcalde-Martin, C. et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Eur. J. Med. Genet. 53, 371\u2013377 (2010).","DOI":"10.1016\/j.ejmg.2010.07.013"},{"key":"871_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0969-2126(97)00185-8","volume":"5","author":"CS Bond","year":"1997","unstructured":"Bond, C. S. et al. Structure of a human lysosomal sulfatase. Struct. (Lond., Engl.: 1993) 5, 277\u2013289 (1997).","journal-title":"Struct. (Lond., Engl.: 1993)"},{"key":"871_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","volume":"32","author":"ER Benjamin","year":"2009","unstructured":"Benjamin, E. R. et al. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J. Inherit. Metab. Dis. 32, 424\u2013440 (2009).","journal-title":"J. Inherit. Metab. Dis."},{"key":"871_CR52","doi-asserted-by":"crossref","unstructured":"Lau, K. C. & Lam, C. W. Molecular investigations of a novel iduronate-2-sulfatase mutant in a Chinese patient. Clin. Chim. Acta 392, 8\u201310 (2008).","DOI":"10.1016\/j.cca.2008.02.009"},{"key":"871_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1126\/science.169.3941.141","volume":"169","author":"EF Neufeld","year":"1970","unstructured":"Neufeld, E. F. & Fratantoni, J. C. Inborn errors of mucopolysaccharide metabolism. Sci. (New York, N. Y.) 169, 141\u2013146 (1970).","journal-title":"Sci. (New York, N. Y.)"},{"key":"871_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1126\/science.181.4101.753","volume":"181","author":"JS O\u2019Brien","year":"1973","unstructured":"O\u2019Brien, J. S., Miller, A. L., Loverde, A. W. & Veath, M. L. Sanfilippo disease type B: enzyme replacement and metabolic correction in cultured fibroblasts. Sci. (New York, N. Y.) 181, 753\u2013755 (1973).","journal-title":"Sci. (New York, N. Y.)"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0871-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:16:01Z","timestamp":1671538561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0871-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"10 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"808"}}